Publications
Specialty
Search
Pharmacy Learning Network
10/23/2024
Nearly 2000 bottles of atovaquone oral suspension distributed by Bionpharma Inc. are under a Class I recall for contamination with Cohnella bacteria.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
10/23/2024
Researchers from Shinshu University developed a simple risk score model using readily measurable health indicators to predict successful MCS weaning. The study analyzed data from 114 patients.
Psych Congress NP Institute, Psych Congress Network
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
Wound Care
10/23/2024
SNN announced that the recently launched RENASYS EDGE Negative Pressure Wound Therapy System has won the Red Dot Award for Design Concepts 2024 in the Medical Devices and Technology Category. SNN previously received the same award in 2021 for the Pico 14 product.
Wound Care
10/23/2024
A Convatec-sponsored post-market CT of 80 patients will determine the efficacy and safety of EDX110 (NO) in DFUs and VLUs resulting from venous insufficiency or diabetes with primary outcome of percentage area reduction at 12 weeks. Not yet recruiting; estimated study completion is Nov 2025. clinicaltrials.gov
Wound Care
10/23/2024
Results of a retro-matched cohort comparing the effectiveness of human keratin matrix (HKM) and SoC in managing full-thickness pressure ulcers found patients treatment with HKM were 2.8 times more likely to experience full wound closure vs SoC group. SAWC Fall 2024 Poster CR-053
Oncology
10/23/2024
According to results from the phase 1b FORT-2 study, 600 mg of rogaratinib is preferable to 800 mg among cisplatin-ineligible patients with FGFR RNA-overexpressing locally advanced or metastatic urothelial cancer being treated with atezolizumab.
Wound Care
10/23/2024
A national pilot survey of 780 patients with hard-to-heal wounds reported that many delay seeking professional assistance (51% more than 3 months), and only 4% see a wound care specialist. The majority (57%) of patients delayed treatment because they believed their wound would heal on its own. J Wound Car
Wound Care
10/23/2024
A study of 12,488 PI/PU patients reported that 50% of all PUs can heal within 20 weeks with optimal SoC. Although Stage 4 lesions took longer to heal, the majority of PUs (Stage 2 and 3) healed by 14 weeks. This data will be used as a benchmark with other studies. SAWC Fall 2024 Poster CR—022
Wound Care
10/23/2024
A 25-patient CT will evaluate the safety and performance of MicroMatrix Flex in subjects with wounds complicated by tunneling and/or undermining features with primary outcome of percentage of closure at 12 weeks measured manually. Not yet recruiting; estimated completion is Mar 2026. clinicatrials.gov
First Report Managed Care
10/23/2024
Research presented at AAN 2024 reveals potential link between small fiber neuropathy and neuropathic pain in people with MS, highlighting the need for further study to better understand the prevalence and mechanisms involved.
First Report Managed Care
10/23/2024
Discover the importance of multidisciplinary team care coordination in managing early-stage NSCLC from an AVAHO 2024 session speaker.
Lymphoma, Leukemia & Myeloma Network, Oncology
10/23/2024
In part 1 of this expert roundtable covering updates in lymphoma from the 2024 Lymphoma, Leukemia & Myeloma Congress, John Leonard, MD, discusses research in indolent lymphomas, highlighting follicular lymphomas, with Matthew Lunning, DO, FACP and Sarah Rutherford, MD.
Wounds, Wound Care
10/23/2024
The Frank & Lizzie Show interviewed Dr Steve Jung, PhD, Chief Technology Office, and AJ Ford, CEO of Engineered Tissue Solutions (ETS) on their revolutionary product, Mirragen, LIVE from SAWC Fall in Las Vegas. Dr Jung walks Frank & Lizzie through what bioactive glass is, how it was developed, and what sets it apart from other products.
First Report Managed Care
10/23/2024
A comprehensive review of multiple sclerosis causes, forms, and treatments.
First Report Managed Care
10/23/2024
The molecular characteristics of primary and metastatic tumors in patients with upper tract urothelial carcinoma (UTUC) are mostly stable, suggesting that oncologists may be able to use analyses of primary tumor samples for molecular subtype-guided treatment of metastases, according to a research team from Weill Cornell Medicine, New York, New York.
First Report Managed Care
10/23/2024
New factor IX therapies promise improved treatment for hemophilia B.
First Report Managed Care
10/23/2024
RNAi therapeutics advance gene silencing with unified nomenclature.
ePlasty, Surgery
10/23/2024
A 55-year-old man experienced proximal rupture of the flexor digitorum profundus tendon while moving heavy furniture, requiring surgical repair.
Oncology
10/23/2024
According to results from the updated analysis of the ShortHER trial, tumor-infiltrating lymphocyte score is predictive of overall survival and may potentially be used to guide trastuzumab de-escalation among patients with HER2-negative early breast cancer.
Reimbursement Library From A to Z
Subscribe and never miss an article!
Today's Wound Clinic Newsletter
